Humate-P
Background
- Human Plasma-derived von Willebrand Factor
- Contains both vWF and factor VIII
Indications
- Hemophilia A (can also use factor VIII, FFP does not work well)
- Von Willebrand disease that is unresponsive to DDAVP (can also use cryoprecipitate, FFP does not work well)
Administration
- Type: blood products
- Dosage Forms:
- Routes of Administration:
- Common Trade Names:
Adult Dosing
- Von Willebrand disease
- Major hemorrhage: loading dose 40-80 IU/kg IV
- Minor hemorrhage: loading dose 40-50 IU/kg IV
- Hemophilia A
- Minor hemorrhage: Loading dose 15 IU/kg IV should achieve FVIII:C plasma level ~30% of normal
- Moderate hemorrhage: Loading dose 25 IU/kg IV should achieve FVIII:C plasma level ~50% of normal
- Life-threatening hemorrhage: 40-50 IU/kg IV initially, followed by 2-25 IU q8-12hr to maintain FVIII:C level at 80-100% of normal
Pediatric Dosing
- Von Willebrand disease
- Major hemorrhage: loading dose 40-80 IU/kg IV
- Minor hemorrhage: loading dose 40-50 IU/kg IV
Special Populations
- Pregnancy Rating: C
- Lactation risk: Data limited
Renal Dosing
- Not delineated
Hepatic Dosing
- Not established
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Respiratory distress
- Anaphylaxis
- Thromboembolic events
- Hemolytic anemia (in massive doses)
Common
- Pain
- Pruritus
- Rash, urticaria, edema
- Fever/chills, flu-like illness, cough, pharyngitis, rhinitis
- Paresthesia
- Fatigue
- Headache
- Asthenia
- Cellulitis
- Chest pain
- Dyspepsia, nausea/vomiting
- Hepatitis
Pharmacology
- Half-life: 10-11h
- Metabolism:
- Excretion:
Mechanism of Action
- Human derived vWF